Investors are pumping billions of dollars into biotechnology startups and paying skyrocketing prices for their stakes in the most-promising new drug companies.
U.S. biotechs rounded up $19.5 billion in venture capital through Sept. 30, topping the $17.4 billion they raised for all of 2019, according to PitchBook Data Inc. and the National Venture Capital Association. This year is on track to double the $12.9 billion that biotechs collected in 2017.
Innovative…
This post first appeared on wsj.com
